- Home
- XENE vs IBRX Comparison
XENE vs IBRX Comparison
Compare XENE & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XENE
- IBRX
- Stock Information
- Founded
- XENE 1996
- IBRX 2014
- Country
- XENE Canada
- IBRX United States
- Employees
- XENE N/A
- IBRX N/A
- Industry
- XENE Biotechnology: Pharmaceutical Preparations
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- XENE Health Care
- IBRX Health Care
- Exchange
- XENE Nasdaq
- IBRX Nasdaq
- Market Cap
- XENE 2.5B
- IBRX 2.4B
- IPO Year
- XENE 2014
- IBRX N/A
- Fundamental
- Price
- XENE $35.54
- IBRX $2.09
- Analyst Decision
- XENE Strong Buy
- IBRX Strong Buy
- Analyst Count
- XENE 9
- IBRX 5
- Target Price
- XENE $56.22
- IBRX $11.35
- AVG Volume (30 Days)
- XENE 862.0K
- IBRX 8.8M
- Earning Date
- XENE 05-12-2025
- IBRX 05-16-2025
- Dividend Yield
- XENE N/A
- IBRX N/A
- EPS Growth
- XENE N/A
- IBRX N/A
- EPS
- XENE N/A
- IBRX N/A
- Revenue
- XENE N/A
- IBRX $14,745,000.00
- Revenue This Year
- XENE N/A
- IBRX $579.28
- Revenue Next Year
- XENE $1,553.36
- IBRX $179.96
- P/E Ratio
- XENE N/A
- IBRX N/A
- Revenue Growth
- XENE N/A
- IBRX 2270.58
- 52 Week Low
- XENE $26.74
- IBRX $1.83
- 52 Week High
- XENE $46.00
- IBRX $9.16
- Technical
- Relative Strength Index (RSI)
- XENE 49.08
- IBRX 37.22
- Support Level
- XENE $37.46
- IBRX $1.83
- Resistance Level
- XENE $39.01
- IBRX $2.63
- Average True Range (ATR)
- XENE 1.68
- IBRX 0.19
- MACD
- XENE -0.14
- IBRX -0.05
- Stochastic Oscillator
- XENE 48.59
- IBRX 25.00
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.